Skip to content

Inventories at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$2.76B+3.4%
Pfizer logo
PfizerPFE
$2.46B-11.9%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.77B+29.9%
Incyte logo
IncyteINCY
$331.42M-9.3%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$1.27B-0.1%
Precigen logo
PrecigenPGEN
$14.73M

Other financials

Income statement

See full
Revenue$20.7M+138%
Gross profit$19.4M+154%
Operating income-$110.0M-3.2%
Net income-$99.1M-11.0%
EPS (diluted)-$1.69-9.0%

Balance sheet

See full
Cash & equivalents$113.6M+43.9%
Total debt$35.7M-32.5%
Total equity$1.1B-24.4%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow-$118.9M-6.7%
CapEx$769.0K+0.4%
Free cash flow-$119.7M-6.6%

Valuation

See full
Market cap$2.12B+18.1%
Enterprise value$2.04B+15.2%
P/S32.1×-16.4×

Profitability

See full
Gross margin90%+2.5pp
Operating margin-720%-204pp
Net margin-639.8%
FCF margin-582.5%-185pp

Returns & leverage

See full
Return on equity-32.8%
Debt / equity0.0×
Current ratio14.2×-4.3×

Where this comes from

Reported directly by Agios Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Agios Pharmaceuticals's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Agios Pharmaceuticals's inventories?
Agios Pharmaceuticals (AGIO) reported inventories of $35.09M in Q1 2026.
How has Agios Pharmaceuticals's inventories changed year-over-year?
Agios Pharmaceuticals's inventories increased by 18.5% year-over-year, from $29.61M to $35.09M.
What is the long-term trend for Agios Pharmaceuticals's inventories?
Over 5 years (2020 to 2025), Agios Pharmaceuticals's inventories has grown at a 17.5% compound annual growth rate (CAGR), from $14.7M to $32.92M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.